SCHEMBL187564

SCHEMBL187564

IN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22959048 0.95
SCHEMBL14392643 0.91
SCHEMBL14087030 0.88
SCHEMBL141116 0.84
SCHEMBL10053863 0.82
SCHEMBL8225474 0.80
SCHEMBL18138135 0.80
SCHEMBL3439854 0.80
SCHEMBL24067530 0.78 KDM4E (0.33)
SCHEMBL18249291 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719592-A1 BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION Centennial Therapeutics, LLC (US) 2026-04-08 EP disclosed
WO-2024249612-A1 BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION CENTENNIAL THERAPEUTICS, LLC (US) 2024-12-05 WO disclosed
US-20230250052-A1 SEPARATION METHOD AGC Inc. (JP) 2023-08-10 US disclosed
US-20220096437-A1 ANTIBACTERIAL COMPOUNDS UNIV BIRMINGHAM (GB) 2022-03-31 US disclosed
US-11253499-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-02-22 US disclosed
EP-3953325-A1 ANTIBACTERIAL COMPOUNDS The University of Birmingham (GB) 2022-02-16 EP disclosed
CN-114008020-A Antibacterial compounds 伯明翰大学 2022-02-01 CN disclosed
EP-3668854-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2022-01-12 EP disclosed
WO-2020206594-A1 ANTIBACTERIAL COMPOUNDS THE UNIVERSITY OF BIRMINGHAM (GB) 2020-10-15 WO disclosed
EP-3668854-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-06-24 EP disclosed
CN-102414194-A Soluble guanylate cyclase activators MERCK SHARP & DOHME 2012-04-11 CN disclosed
US-20120035122-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC 2012-02-09 US disclosed
WO-2012017359-A1 ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-02-09 WO disclosed
WO-2012003498-A1 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed
EP-2401265-A2 SOLUBLE GUANYLATE CYCLASE ACTIVATORS Merck Sharp & Dohme Corp. (US) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed
WO-2010099054-A2 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. (US) 2010-09-02 WO disclosed
US-20100216764-A1 Soluble Guanylate Cyclase Activators MERCK SHARP & DOHME LLC 2010-08-26 US disclosed
US-20100022507-A1 AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-01-28 US disclosed
WO-2007015855-A1 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2007-02-08 WO disclosed